Last reviewed · How we verify

Famotidine 20 MG — Competitive Intelligence Brief

Famotidine 20 MG (Famotidine 20 MG) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Histamine-2 Receptor Antagonist [EPC].

marketed Histamine-2 Receptor Antagonist [EPC] Small molecule Live · refreshed every 30 min

Target snapshot

Famotidine 20 MG (Famotidine 20 MG) — Chattogram General Hospital.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Famotidine 20 MG TARGET Famotidine 20 MG Chattogram General Hospital marketed Histamine-2 Receptor Antagonist [EPC]
Axid Ar NIZATIDINE marketed Histamine-2 Receptor Antagonist [EPC] Histamine H2 receptor 1988-01-01
Pepcid famotidine Generic (originally Yamanouchi/Merck) marketed Histamine-2 Receptor Antagonist [EPC] Multidrug and toxin extrusion protein 1, Multidrug and toxin extrusion protein 2, Solute carrier family 22 member 2 1986-10-01
Tagamet CIMETIDINE marketed Histamine-2 Receptor Antagonist [EPC] Histamine H2 receptor 1977-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Histamine-2 Receptor Antagonist [EPC] class)

  1. · 2 drugs in this class
  2. Chattogram General Hospital · 1 drug in this class
  3. Generic (originally Yamanouchi/Merck) · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Famotidine 20 MG — Competitive Intelligence Brief. https://druglandscape.com/ci/famotidine-20-mg. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: